researcher comment: the keynote-355 trial | javier cortes
Published 4 years ago • 738 plays • Length 5:37Download video MP4
Download video MP3
Similar videos
-
4:53
chemoimmunotherapy in tnbc: the keynote-355 trial
-
1:30
keynote-355: hrqol unaffected by the addition of pembrolizumab to chemotherapy for tnbc
-
4:49
keynote-355: pembro chemo in triple-negative breast cancer
-
2:34
esmo 2021 breast cancer highlights: tulip and keynote-355
-
2:07
keynote-355: pembrolizumab in triple-negative breast cancer
-
14:32
my experience so far with keytruda immunotherapy (cancer treatment)
-
31:24
harnessing the immune system in the treatment of triple-negative breast cancer
-
50:36
31. cancer 3
-
12:45
keynote-355: first-line pembrolizumab plus chemotherapy for metastatic triple-negative breast ca...
-
4:54
hope rugo, md, shares the design and outcomes of keynote-355 presented at sabcs 2020
-
5:39
researcher comment: the ecog-acrin e2108 trial | seema khan
-
4:11
asco 2020: pembrolizumab plus chemotherapy for patients with metastatic triple-negative breast c...
-
18:38
breast cancer esmo 2024 highlights: key studies discussed natalee, keynote 522, destiny-breast12
-
22:13
part 2 - management of triple-negative metastatic breast cancer - dr. javier cortes, barcelona
-
2:24
keynote-355: pembrolizumab in triple-negative breast cancer
-
0:43
management of residual disease in triple negative breast cancer
-
21:00
precision medicine in metastatic triple negative breast cancer
-
1:42
hope rugo, md, offers key takeaways for physicians regarding keynote-355
-
1:34:57
cancer: how do we prevent metastasis?
-
5:54
case 3: treatment after progression in triple-negative breast cancer
-
1:35
longer overall survival in metastatic tnbc with pembrolizumab - medpage today